6 citations
,
January 2024 in “Journal of Biotechnology and Biomedicine” Atopic dermatitis needs personalized treatment using various therapies, starting with topical corticosteroids.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
April 2018 in “Journal of Investigative Dermatology” Kaempferol helps skin stem cells grow and may improve skin thickness due to its 3-OH group.
April 2018 in “Journal of Investigative Dermatology” Removing STAT5 from 3D-cultured human skin cells reduces their ability to grow hair.
April 2018 in “Journal of Investigative Dermatology” Ginsenoside Rd may help improve skin aging by increasing collagen in the skin.
April 2018 in “Journal of Investigative Dermatology” Aging reduces skin cell renewal and defense against germs due to TGFbeta, but blocking TGFbeta could help restore these functions.
April 2018 in “Journal of Investigative Dermatology”
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
1 citations
,
October 2021 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for severe alopecia areata show promise but lack standard approval.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.
January 2022 in “Dermatology Review” Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
148 citations
,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
23 citations
,
June 2012 in “Molecular Biology Reports” VEGF stimulates hair cell growth and increases growth receptor levels through a specific signaling pathway.
22 citations
,
November 2024 in “Planta” Aromatic plants can naturally help prevent skin aging and improve skin health.
14 citations
,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
5 citations
,
June 2022 in “Frontiers in immunology” Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
2 citations
,
October 2024 in “Dermatology and Therapy” Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.
1 citations
,
November 2025 in “Clinical and Experimental Medicine” lncRNAs are important for understanding and treating skin diseases.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
January 2026 in “Dermatology and Therapy”
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.